CHPM (Chinese Herbal Patent Medicine ): Pugongying (Herba Taraxaci) Granules, 15g/tid for 3 days, follow-up for 7 days.
Education, basic medical order.

CHPM (Chinese Herbal Patent Medicine): Pugongying (Herba Taraxaci) granules, 15g/tid for 3 days, follow-up for 7 days.
Antibiotics: Cefdinir Capsules, 0.1g/tid for 2 days, follow-up for 7 days.
Education, basic medical order.

Antibiotics: Cefdinir Capsules, 0.1g/tid for 3 days, follow-up for 7 days.
Education, basic medical order.

Mastitis Acute Female

Pugongying (Herba Taraxaci) granules is named as Pugongying Granules in China and produced by Kunming pharmaceutical factory co. LTD. The form is granules, and the participants will take the medicine after dissolved as 15g/tid for 3 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.

CHPM (Chinese Herbal Patent Medicine )

Cefdinir Capsules is also named as Cefdinir and produced by Astellas Pharma Inc. The form is capsule, and participants will take orally the capsules with water as 0.1g/tid for 3 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.

Antibiotics Cefdinir Capsules

Doctors will give suggestions and the medical orders to all participants, including dietary, emotional regulation and the knowledge of breast-feeding.

Education

Cefdinir Capsules is also named as Cefdinir and produced by Astellas Pharma Inc. The form is capsule, and participants will take orally the capsules with water as 0.1g/tid for 2 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.

Beijing Hospital of Traditional Chinese Medicine

Beijing University of Chinese Medicine Third Affiliated Hospital

Tongzhou Maternal & Child Health Hospital of Beijing

The Effect of Chinese Herbal Medicine for Reducing the Application of Antibiotics in the Treatment of Acute Mastitis

The Effect of Chinese Herbal Medicine for Reducing the Application of Antibiotics in the Treatment of Acute Mastitis With Three Groups in Randomized Controlled Trial.

Body temperature will be measured by mercury thermometer and recorded on the prepared card by participants. The temperature of the participants reduces to 37.2℃ or more below, assessing as the normal temperature. And the normal temperature last for at least 24 hours, considered as fever-relief.
To evaluate the effect of drug action time and the temperature changing from the baseline to the end of 3-day treatment.

Pain of breast will be self-reported by participants and recorded. A visual analog scale (VAS) is used to assess breast pain. The scale was tested in the investigator's previous trial. 0 score indicates "no uncomfortable feeling". 1-3 indicates "mild uncomfortable feeling". 4-6 indicates "moderate uncomfortable feeling". 7-10 indicates "severe uncomfortable feeling".
To evaluate the changing from the baseline to the end of 3-day treatment.

The masses are manual outlined by the outcome assessor.
To evaluate the changing from the baseline to the end of 3-day treatment.

The 0-3 scores are used to describe the patency of milk from no stagnation to severe stagnation. 0 indicates that there is no stagnation with breast and milk spurts out by slightly pressure; 1 indicates mild stagnation and milk flows by more pressure; 2 indicates moderate stagnation and milk drops out by much more pressure; 3 indicates there is severe stagnation and no milk excreted. The outcome will be measured by the outcome assessor.
To evaluate the changing from the baseline to the end of 3-day treatment.

The assessment criteria refer to Standard of diagnosis and treatment in TCM symptoms (2016 version, released by State Administration of Traditional Chinese Medicine of the People's Republic of China). The outcome is specifically used to assess the holistic physical status of the participants and will be measured by TCM practitioners.
To evaluate the changing from the baseline to the end of 3-day treatment.

Measured by the routine blood test.
To evaluate the changing from the baseline to the end of 3-day treatment.

Adverse events are assessed by CTCAE (version 5.0, released by NIH and NIC). The outcomes measured at baseline are used to determine whether the participants are eligible to participate the study and the outcomes measured during and after 3-day treatment are used to assess the safety of the intervention medicine and to protect the rights of the participants.
To focus on (1) allergic reaction; (2) the vital signs: resting heart rate in times/minutes, respiratory rate in times/minutes and blood pressure in mmHg; (3) laboratory test: urinalysis (LEU, BLO, KET, NIH, GLU, PRO, UBG, SG) in positive/negative, stool routine (Sed occult blood) in postive/negative, electrocardiogram in normal/abnormal, liver function test (AST, ALT, TBIL, DBIL, TG, GLU) in positive/negative and renal function test (CR, UA, UREA) in positive/negative.
To observe the incidence of the adverse events.

After 3-day treatment, the participants will be followed up for 3 days to figure out the incidence of acute mastitis relapse. The investigators will call the participants to inquiry their conditions (body temperature, breast pain, amount of milk).

After 3-day treatment, clinical evaluation will be conducted by doctors. If B-ultrasound shows there is mammary abscess, the doctor will perform surgery based on liquefaction and size of the abscess.

After 3-day treatment, clinical evaluation will be conducted by doctors. If B-ultrasound shows there is mammary abscess, the doctor will prescribe Cefdinir or Pugongying granules based on liquefaction and size of the abscess.

Xiaohua Pei

Principal Investigator, Clinical Professor, Academic Leader of Breast Disease in Traditional Chinese Medicine.

Beijing University of Chinese Medicine

Based on previous studies, considering the 20% expulsion rate, the investigators plan to recruit 306 participants with sample-size calculation formula. The sequence of randomization (1:1:1) will be generated by the statisticians with a computer program.

Due to the different numbers of interventions, the investigators can not blind the participants and the doctors. Thus, the CRF recorders, outcomes assessors and the statisticians will be blinded in the study.

Postpartum Hemorrhage

Recruiting only pregnant women prior to child-birth delivery.

misoprostol

Queens Hospital Center

Effect of Adjunctive Misoprostol Treatment on Blood Loss at Vaginal Delivery

Effect of Adjunctive Misoprostol on Blood Loss at Vaginal Delivery

Aleksandr Fuks

Directore, Department OB / GYN , Queens Hospital Center

New York City Health and Hospitals Corporation

Traumatic Brain Injury

IV Progesterone

Emory University School of Medicine - Dept. of Emergency Medicine

Progesterone Treatment of Blunt Traumatic Brain Injury

ProTECT: Single Center, Phase II (Pilot), Double Blind, 4:1 Randomized, Placebo Controlled Clinical Trial for Progesterone Treatment of Moderate and Severe Blunt TBI

mastodynia/fiabhras

The Effect of Chinese Herbal Medicine for Reducing the Application of Antibiotics in the Treatment of Acute Mastitis

Effect of Adjunctive Misoprostol Treatment on Blood Loss at Vaginal Delivery

Progesterone Treatment of Blunt Traumatic Brain Injury

An bunachar luibheanna míochaine is iomláine le tacaíocht ón eolaíocht